Mankind Pharma’s board has approved the unaudited financial results for the second quarter (Q2) of FY26. The company reported a consolidated net profit of ₹520.18 crore and revenue from operations reached ₹3,697.16 crore. The company also disclosed updates regarding the scheme of amalgamation with its subsidiaries and the transfer of its OTC business. The financial performance showcases Mankind Pharma’s continued growth and profitability in the pharmaceutical sector.
Financial Performance Highlights
The Board of Directors of Mankind Pharma has approved the unaudited consolidated financial results for the quarter ended September 30, 2025. Key highlights include:
- Revenue from operations: ₹3,697.16 crore
- Net Profit: ₹520.18 crore
Segmental Performance
The company operates primarily in the pharmaceuticals and healthcare products segment, and the financial results reflect the performance of this segment.
Strategic Updates
Several strategic initiatives were highlighted during the board meeting:
- The scheme of amalgamation between the company and its subsidiaries (Shree Jee Laboratory Private Limited, JPR Labs Private Limited and Jaspack Industries Private Limited) has been completed, with appointed date effective from April 1, 2024.
- Transfer of the Over the Counter (OTC) Business of the Company to its wholly owned subsidiary company, Mankind Consumer Products Private Limited was completed on September 30, 2024.
Additional Investments
During Q2, the company invested in its subsidiary companies. Detailed specifics of the investments are as follows:
- Lifestar Pharmaceuticals Private Limited.
- Mankind Life Sciences Private Limited
- Mankind Agritech Private Limited
- Mankind Medicare Private Limited
- Mankind Prime Labs Private Limited
Stock Options Update
The company has also issued and allotted stock options under its Mankind Employees Stock Option Plan 2022 (ESOP-2022).
Business Acquisition
The Board of directors approved the acquisition of the Branded Generic Business relating to the Women’s Health Portfolio from Bharat Serums and Vaccines Limited. This will be effective November 1, 2025.
Source: BSE
